6A550ZV is a valid billable ICD-10 procedure code for Pheresis of Hematopoietic Stem Cells, Single . It is found in the 2022 version of the ICD-10 Procedure Coding System (PCS) and can be used in all HIPAA-covered transactions from Oct 01, 2021 - Sep 30, 2022 .
6A550ZV is a valid billable ICD-10 procedure code for Pheresis of Hematopoietic Stem Cells, Single . It is found in the 2022 version of the ICD-10 Procedure Coding System (PCS) and can be used in all HIPAA-covered transactions from Oct 01, 2021 - Sep 30, 2022 . Extracorporeal separation of blood products.
Autologous donor, stem cells. Z52.011 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM Z52.011 became effective on October 1, 2018.
30243C0 is a billable procedure code used to specify the performance of transfusion of autologous hematopoietic stem/progenitor cells, genetically modified into central vein, percutaneous approach. The code is valid for the year 2022 for the submission of HIPAA-covered transactions.
The ICD-10 Procedure Coding System (ICD-10-PCS) is a catalog of procedural codes used by medical professionals for hospital inpatient healthcare settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates. These 2022 ICD-10-PCS codes are to be used for discharges occurring from October 1, 2021 through September 30, 2022.
6A550ZV is a billable procedure code used to specify the performance of pheresis of hematopoietic stem cells, single. The code is valid for the year 2021 for the submission of HIPAA-covered transactions.
In addition to the nationally covered indications for HPC, allogenic, the following indications will be covered locally, for those jurisdictions or providers for whom this Medical Policy article applies, when medically necessary:
The correct use of an ICD-10-CM code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination.
HPC, autologous in combination with high dose melphalan for patients with primary amyloid light chain amyloidosis, with amyloid deposition in two or fewer organs and a cardiac left ventricular ejection fraction greater than 45%.
Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the CED paradigm: